| Revue: | Revista médica del Instituto Mexicano del Seguro Social |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000356462 |
| ISSN: | 0443-5117 |
| Autores: | Meneses García, Abelardo1 Ramírez, Teresa2 Ruiz Godoy, Luz3 Chiquete, Erwin4 Mohar, Alejandro4 |
| Instituciones: | 1Instituto Nacional de Cancerología, Dirección Médica, México, Distrito Federal. México 2Instituto Nacional de Cancerología, Departamento de Cáncer de Mama, México, Distrito Federal. México 3Instituto Nacional de Cancerología, Banco de Tumores, México, Distrito Federal. México 4Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Distrito Federal. México |
| Año: | 2012 |
| Periodo: | Ene-Feb |
| Volumen: | 50 |
| Número: | 1 |
| Paginación: | 19-24 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Background: the aim was to perform a cost analysis on direct data of integral medical care provided to BC patients prior to introduction of immunotherapy. Methods: a total of 633 patients were studied. Direct costs calculations were performed on individual patient data in a subset of 309 randomly selected patients, extrapolating calculations to the universe of 633 patients. Information was obtained for each management process (diagnosis and staging, cancer management, symptoms control, palliative care and follow-up). Costs are expressed in 2008 US dollars (USD) and adjusted to a 3 % discount rate. Results: the clinical stage distribution in the 633 patients was 41, 191, 240 and 58 patients for clinical stages I to IV, respectively; with 103 patients referred from other institutions without staging. The annual costs of care per patient was, in clinical stage I: 6,219,94 USD; stage II: 7,498.04 USD; stage III: 9,610.31 USD; stage IV: 9,917.82 USD; and in patients without staging: 7,504.41 USD. The exact total integral cost according to the universe of BC patients (n = 633) by 2004 was 5,341,805.37 USD. Conclusions: before the introduction of immune-based therapy costs of care for Mexican women with BC increased with advanced stages do to a significant proportion of patients were diagnosed late |
| Disciplinas: | Medicina |
| Palabras clave: | Oncología, Terapéutica, Cáncer, Mama, Costo de tratamiento, Análisis de costos, Trastuzumab |
| Keyword: | Medicine, Oncology, Therapeutics, Cancer, Breast, Treatment cost, Cost analysis, Trastuzumab |
| Texte intégral: | Texto completo (Ver HTML) |
